-

Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Li-Cycle Holdings Corp. (LICY) f/k/a Peridot Acquisition Corp. (PDAC)

SAN DIEGO--(BUSINESS WIRE)--The Class: Shareholder rights law firm Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Li-Cycle Holdings Corp. (NYSE: LICY) securities between February 16, 2021 and March 23, 2022, for violations of the Securities Exchange Act of 1934. Li-Cycle purports to be an industry leader in lithium-ion battery resource recovery and the leading lithium-ion battery recycler in North America.

If you would like more information about Li-Cycle Holdings Corp.'s misconduct, click here.

What is this Case About: Li-Cycle Holdings Corp. (LICY) Failed to Disclose its Business Failings to Investors

According to the complaint, Li-Cycle merged with Peridot Acquisition Corp., a special purpose acquisition company, on August 10, 2021. During the class period, defendants touted Li-Cycle's patented technology and noted that the merger would enable Li-Cycle "to fully fund its planned global expansion." However, defendants failed to disclose that Li-Cycle's largest customer was merely a broker providing working capital financial to the Company while trying to sell the product to end customers. Further, Li-Cycle engaged in questionable related party transactions. With regard to accounting, the Company gave a false impression of growth, reported revenues derived by marking up receivables on unsold products, and concealed that the Company would need an additional $1 billion to support planned growth.

The truth came to light on March 24, 2022, when market researcher Blue Orca Capital released a report describing the Company as "a near fatal combination of stock promotion, laughable governance, a broker business hemorrhaging cash, and highly questionable Ernon-like accounting" and detailing the Company's failings. On this news, Li-Cycle's shares fell approximately 5.6%, to close at $7.93 per share on March 24, 2022.

Next Steps: If you acquired shares of Li-Cycle Holdings Corp. (LICY) between February 16, 2021 and March 23, 2022, you have until June 20, 2022, to ask the court to appoint you lead plaintiff for the class. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Li-Cycle Holdings Corp. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NYSE:LICY

Release Summary
Li-Cycle Holdings Corp. (LICY) Failed to Disclose its Business Failings to Investors
Release Versions
$Cashtags

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Regencell Bioscience Holdings Limited Class Action Reminder - Robbins LLP Encourages RGC Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Regencell Bioscience Holdings Limited (NASDAQ: RGC) securities between October 28, 2024 and October 31, 2025. Regencell is a purported early-stage bioscience company focused on the research, development, and commercialization of traditional Chinese medicine (“TCM”) for the treatment of attention-deficit/hyperactivity disorder (“ADHD”) and autis...

POET Technologies Inc. Class Action Reminder - Robbins LLP Encourages POET Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired POET Technologies Inc. (NASDAQ: POET) securities between April 1, 2026 and 8:57 A.M. ET on April 27, 2026. POET Technologies describes itself as a "design and development company offering photonic integrated packaging solutions based on the POET Optical Interposer™, a novel platform that allows the seamless integration of electronic and photoni...

Immutep Limited Class Action Reminder - Robbins LLP Encourages IMMP Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP is Investigating Allegations that Immutep Limited (IMMP) Misled Investors Regarding the Viability and Efficacy of its Drug CandidateOn May 5, 2026, a class action was filed on behalf of all investors who purchased or otherwise acquired Immutep Limited American Depository Receipts (NASDAQ: IMMP) between March 24, 2025 and March 12, 2026. Immutep is an Australian-based biotechnology company focused on developing Lymphocyte Activation Gene-3 (LAG-3) related i...
Back to Newsroom